Hypertermic Intrathoracic Chemotherapy (HITHOC) for thymoma: a narrative review on indications and results

被引:12
作者
Aprile, Vittorio [1 ]
Bacchin, Diana [1 ]
Korasidis, Stylianos [1 ]
Ricciardi, Roberta [2 ]
Petrini, Iacopo [3 ]
Ambrogi, Marcello Carlo [1 ]
Lucchi, Marco [1 ]
机构
[1] Univ Pisa, Cardiac Thorac & Vasc Dept, Thorac Surg, Pisa, Italy
[2] Univ Pisa, Dept Clin & Expt Med, Neurol Unit, Pisa, Italy
[3] Univ Hosp Pisa, Dept Crit Area & Surg, Unit Resp Med, Med & Mol Pathol, Pisa, Italy
关键词
Hypertermic intrathoracic chemotherapy (HITHOC); thymoma; intracavitary chemotherapy; hyperthermia; redo-surgery; MALIGNANT PLEURAL MESOTHELIOMA; CYTOREDUCTIVE SURGERY; INTRAPLEURAL PERFUSION; CISPLATIN; RECURRENCE; RESECTION; PHARMACOKINETICS; HYPERTHERMIA; FEASIBILITY; PLEURECTOMY;
D O I
10.21037/atm-20-6704
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: With this narrative review, we retraced the history of hypertermic intrathoracic chemotherapy (HITHOC) since the beginning, analyzing literature on operative technique, feasibility and efficacy of this treatment. Moreover, we report the fifteen-year experience of our center in this relatively new technique, for what concerns both early postoperative results and long-term oncological outcomes. Background: Thymomas are frequently misdiagnosed and recognized in advanced stage, often with pleural dissemination, especially when not associated to Myasthenia Gravis that allows an early diagnosis during the initial assessment. Moreover, the natural history of locally advanced thymoma is characterized by a high rate of pleural or pericardial relapses. Surgery has always been considered a milestone in thymoma's treatment, even in case of serous dissemination or relapses, although his role as exclusive therapy does not guarantee an acceptable local disease control. In case of disseminated disease, different multidisciplinary protocols have been experimented, from chemotherapy to radiation therapy, alone or associated to surgery, in order to increase overall and disease-free survival, but the breakthrough happened in the early 90s with the introduction of HITHOC following surgery. Combination of surgery and HITHOC resulted in less toxic than systemic chemotherapy and providing a good local disease control in patients with stage IVa thymomas or thymoma's pleural recurrences. Methods: We searched PubMed for relevant literature, up to January 2020, on hypertermic intrapleural chemotherapy for thymomas (TPR or DNT), selecting only those reporting information about HITHOC protocol used, postoperative course and oncological outcomes. Conclusions: HITHOC is a safe and feasible procedure, with a very low complication rate and negligible systemic effects of chemotherapeutic agents, effective in controlling both TPR and DNT, in particular as regards local disease-free survival.
引用
收藏
页数:12
相关论文
共 43 条
  • [11] Feasibility of multimodality therapy including extended resections in stage IVA thymoma
    Huang, James
    Rizk, Nabil P.
    Travis, William D.
    Seshan, Venkatraman E.
    Bains, Manjit S.
    Dycoco, Joseph
    Downey, Robert J.
    Flores, Raja M.
    Park, Bernard J.
    Rusch, Valerie W.
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2007, 134 (06) : 1477 - 1484
  • [12] Jacquet P, 1998, CANCER CHEMOTH PHARM, V41, P147
  • [13] Lymphogenous and hematogenous metastasis of thymic epithelial tumors
    Kondo, K
    Monden, Y
    [J]. ANNALS OF THORACIC SURGERY, 2003, 76 (06) : 1859 - 1864
  • [14] Retrospective analysis on the safety of 5,759 times of bedside hyperthermic intra-peritoneal or intra-pleural chemotherapy (HIPEC)
    Liu, Lili
    Zhang, Ning
    Min, Jie
    Su, Haichuan
    Wang, Hongmei
    Chen, Dongxu
    Sun, Li
    Zhang, Hongwei
    Li, Wei
    Zhang, Helong
    [J]. ONCOTARGET, 2016, 7 (16) : 21570 - 21578
  • [15] Matsuzaki Y, 2008, ANN THORAC CARDIOVAS, V14, P161
  • [16] Intra-Thoracic Chemo-Hyperthermia for pleural recurrence of thymomas
    Maury, Jean-Michel
    Drevet, Gabrielle
    Tronc, Francois
    Girard, Nicolas
    [J]. JOURNAL OF THORACIC DISEASE, 2017, 9 (12) : E1137 - E1139
  • [17] Does cytoreduction surgery and hyperthermic intrathoracic chemotherapy prolong survival in patients with N0-N1 nonsmall cell lung cancer and malignant pleural effusion?
    Migliore, Marcello
    Nardini, Marco
    [J]. EUROPEAN RESPIRATORY REVIEW, 2019, 28 (153)
  • [18] IMMUNOHISTOLOGICAL EVIDENCES OF CORTICAL AND MEDULLARY DIFFERENTIATION IN THYMOMA
    MULLERHERMELINK, HK
    MARINO, M
    PALESTRO, G
    SCHUMACHER, U
    KIRCHNER, T
    [J]. VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1985, 408 (2-3) : 143 - 161
  • [19] BIOLOGICAL AND CLINICAL ASPECTS OF HYPERTHERMIA IN CANCER-THERAPY
    OLESON, JR
    CALDERWOOD, SK
    COUGHLIN, CT
    DEWHIRST, MW
    GERWECK, LE
    GIBBS, FA
    KAPP, DS
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1988, 11 (03): : 368 - 380
  • [20] OVERGAARD J, 1977, CANCER-AM CANCER SOC, V39, P2637, DOI 10.1002/1097-0142(197706)39:6<2637::AID-CNCR2820390650>3.0.CO